Type of information: Treatment of the first patient
Announcement: treatment of the first patient
Company: OncoMed Pharmaceuticals (USA - CA)
Product: OMP-313M32 (anti-TIGIT)
Action mechanism: monoclonal antibody/immune checkpoint inhibitor. OMP-313M32 is an anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibody. TIGIT is expressed on many different tumor types. It blocks T cells from attacking tumor cells and is similar in structure and function to the inhibitory protein PD-1. OMP-313M32 is intended to activate the immune system through multiple mechanisms and enable anti-tumor activity. In preclinical studies, anti-TIGIT antibodies increased cytotoxic T-cell activity against tumor cells and decreased T-cell suppression. Anti-TIGIT antibodies also demonstrated combination activity with checkpoint inhibitors anti-PD1 and anti-PD-L1 in preclinical models.
Disease: solid tumors
Therapeutic area: Cancer - Oncology
Trial details: The purpose of this study is to evaluate the safety and efficacy of OMP-31M32. OMP-313M32 is an experimental anti-TIGIT antibody that was developed to block TIGIT from binding PVR allowing the body's T-cells to destroy cancer cells. (NCT03119428)